New agents for acute myelogenous leukemia

Leukemia

Volumn 14, Issue 3, 2000, Pages 488-490

  Zwiebel, J A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Fenretinide; Histone acetylation; Leukemia; Protein kinase

Indexed keywords

HISTONE; PROTEIN KINASE INHIBITOR; RETINOID;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034010117     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401662     Document Type: Conference Paper

References (24)

1. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
2. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
3. He LZ, Guidez F, Tribioli C et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL. Nat Genet 1998; 18: 126-135.
4. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998; 16: 2549-2556.
5. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
6. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191.
7. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t (8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
8. Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998; 91: 2631-2633.
9. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t (8:21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
10. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401-1408.
11. Lea MA, Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995; 15: 879-883.
12. Yu KH, Weng LJ, Fu S, Piantadosi S, Gore SD. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia 1999; 13: 1258-1265.
13. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
14. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
15. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
16. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971; 285: 1182-1186.
17. Nguyen M, Watanabe H, Budson AE, Richie JP, Haves DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-361.
18. Perez-Atayde AR. Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
19. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
20. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 1997; 52: 1000-1009.
21. Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer 1998; 78: 248-254.
22. Reed JC. Fenretinide: the death of a tumor cell. J Natl Cancer Inst 1999; 91: 1099-1100.
23. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retionic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-410.
24. Bagniewski PG, Reid JM, Villablanca JG, Reynolds CP, Ames MM. A phase I pharmacokinetic study of fenretinide in children with high-risk solid tumors. AACR Proc 1999; 40: 92.